查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球腎纖維化治療市場研究與預測：按治療劑、最終用戶和地區分列的分析，2022-2029 年
市場調查報告書
商品編碼
1151999

全球腎纖維化治療市場研究與預測：按治療劑、最終用戶和地區分列的分析，2022-2029 年

Global Kidney Fibrosis Treatment Market Size study & Forecast, by Therapeutics, by End User and Regional Analysis, 2022-2029
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3個工作天內

價格

腎纖維化是指細胞外基質 (ECM) 蛋白在腎臟間質中的過度產生和沈積。

這種 ECM 的過度產生和沈積會導致結構損傷和腎功能下降，從而導致終末期腎病 (ESRD)。腎纖維化的兩個主要原因是糖尿病和高血壓。傳染性腎小球腎炎、腎血管炎、輸尿管梗阻、遺傳異常、自身免疫性疾病等也會引起腎纖維化。慢性腎髒病發病率的增加、腎纖維化治療意識的提高以及主要市場參與者的戰略舉措是推動市場增長的關鍵因素。

根據疾病控制和預防中心的數據，到 2021 年，大約 3700 萬美國人將患有慢性腎病，佔所有美國成年人的 15% 以上。此外，國家腎臟基金會估計，美國七分之一以上的成年人被診斷患有慢性腎病。此外，大約 90% 的腎病患者並不知道自己的疾病。此外，政府當局越來越積極的舉措以及與生活方式相關的疾病患病率上升也有望在預測期內為市場提供良好的增長前景。然而，與監管審批相關的複雜流程將阻礙整個 2022-2029 年預測期內的市場增長。

全球腎纖維化治療市場研究考慮的主要區域包括亞太地區、北美、歐洲、拉丁美洲和世界其他地區。由於慢性腎病患病率的增加以及該地區政府當局的積極舉措，北美已成為市場份額方面的領先地區。另一方面，由於醫療費用增加以及高血壓和糖尿病等生活方式相關疾病的流行，預計亞太地區在預測期內將出現顯著增長。

本報告中的主要市場進入者包括：

  • Merck & Co.
  • F. Hoffman-La Roche Ltd.
  • Pfizer Inc.
  • Galectin Therapeutics
  • La Jolla Pharmaceutical Company
  • InterMune Inc.
  • ProMetic Life-Sciences Inc.
  • Genzyme Corporation
  • BioLine Rx Ltd
  • Certa Therapeutics

近期市場動態。

  • 2022 年 3 月，Zydus Lifesciences 獲得了印度藥品監管局（DCGI）批准的名為 Oxemia 的新藥申請（NDA）。新藥 Oxemia 是印度首個用於治療與慢性腎病 (CKD) 相關的貧血的口服藥物。
  • 2022年8月，Bayer在印度推出治療2型糖尿病相關慢性腎病的新藥Finelenone。這種新藥將以 Kerendia 品牌在印度上市銷售。
  • 2022 年 8 月，費城兒童醫院 (CHOP) 和 Penn Medicine 宣布他們將聯合啟動 Penn-CHOP 腎臟創新中心。新中心將是世界上第一個推進腎臟疾病及其相關並發症的早期檢測、預防和治療研究的中心。

全球腎纖維化治療市場研究範圍。

歷史數據： 2019-2020-2021

基準估計年份：2021

預測期：2022-2029

報告的收入預測、公司排名、競爭格局、增長因素、趨勢

目標細分治療劑、最終用戶、地區

區域範圍北美、歐洲、亞太地區、拉丁美洲、世界其他地區

購買調查覆蓋率報告可免費獲得定制（相當於最多 8 個分析師小時）。添加或更改國家、地區、航段範圍*

這項研究的目的是定義近年來各個細分市場和國家的市場規模，並預測他們在未來幾年的價值。該報告旨在捕捉被調查國家工業的定性和定量方面的情況。

它還提供了有關關鍵方面的詳細信息，例如將定義市場未來增長的驅動因素和挑戰。此外，它還包含供利益相關者投資的微觀市場潛在機會，以及對主要參與者的競爭格局和產品供應的深入分析。市場的詳細細分和子細分如下所述。

按藥物

血管緊張素 II 受體阻滯劑 (ARB)

血管緊張素轉換□ (ACE) 抑製劑

□非尼酮

腎素抑製劑

血管□□抑製劑

按最終用戶

醫院

診所

家庭醫療

按地區

北美

美國

加拿大

歐洲

英國

德國

法國

西班牙

意大利

歐洲其他地區

亞太地區

中國

印度

日本

澳大利亞

韓國

其他亞太地區

拉丁美洲

巴西

墨西哥

世界其他地區

目錄

第一章內容提要

  • 市場快照
  • 2019-2029 年按細分市場的全球市場估計和預測
    • 腎纖維化治療市場：按地區劃分，2019-2029
    • 腎纖維化治療市場：按治療藥物分類，2019-2029
    • 腎纖維化治療市場：按最終用戶分類，2019-2029
  • 主要趨勢
  • 調查方法
  • 調查先決條件

第二章腎纖維化治療的全球市場定義和範圍

  • 調查目的
  • 市場定義和範圍
    • 調查範圍
    • 產業進化
  • 調查目標年份
  • 貨幣兌換率

第三章全球腎纖維化治療市場動態

  • 腎纖維化治療市場影響分析（2019-2029）
    • 市場驅動力
      • 慢性腎髒病發病率增加
      • 對腎纖維化治療的認識不斷提高。
      • 主要市場參與者的戰略舉措。
    • 市場挑戰
      • 複雜的監管審批流程
    • 市場機會
      • 政府當局的有利舉措增加。
      • 生活方式相關疾病的傳播

第四章全球腎纖維化治療市場行業分析

  • 波特五力模型
    • 供應商的議價能力
    • 買方議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭對手之間的競爭
  • 波特五力模型的未來方法（2019-2029）
  • PEST分析
    • 政治的
    • 經濟的
    • 社會的
    • 技術的
  • 招商引資模式
  • 分析師結論/建議
  • 頂級投資機會
  • 關鍵成功策略

第 5 章風險評估：COVID-19 的影響

  • 評估 COVID-19 對行業的整體影響
  • COVID-19 之前和 COVID-19 之後的市場情景

6 全球腎纖維化治療市場，按治療劑

  • 市場快照
  • 全球腎纖維化治療市場：治療學的性能潛力分析
  • 2019-2029 年全球腎纖維化治療市場、治療學估計和預測
  • 腎纖維化治療市場，細分分析
    • 血管緊張素 II 受體阻滯劑 (ARB)
    • 血管緊張素轉換□ (ACE) 抑製劑
    • □非尼酮
    • 腎素抑製劑
    • 血管□□抑製劑

7 全球腎纖維化治療市場，按最終用戶

  • 市場快照
  • 全球腎纖維化治療市場：最終用戶的性能潛力分析
  • 全球腎纖維化治療市場、最終用戶估計和預測（2019-2029）
  • 腎纖維化治療市場，細分分析
    • 醫院
    • 診所
    • 家庭治療

8 全球腎纖維化治療市場：區域分析

  • 腎纖維化治療市場的區域市場概況
  • 北美
    • 美國
      • 治療藥物的估計和預測，2019-2029
      • 最終用戶的估計和預測，2019-2029
    • 加拿大
  • 歐洲腎纖維化治療市場概況
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 意大利
    • 歐洲其他地區
  • 亞太地區腎纖維化治療市場概況
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 韓國
    • 亞太其他地區
  • 拉丁美洲腎纖維化治療市場概況
    • 巴西
    • 墨西哥
  • 世界其他地區

第 9 章 競爭信息

  • 頂級市場戰略
  • 公司簡介
    • Merck & Co.
      • 主要信息
      • 概述
      • 財務（取決於數據可用性）
      • 產品概要
      • 近期發展狀況
    • F. Hoffman-La Roche Ltd.
    • Pfizer Inc
    • Galectin Therapeutics
    • La Jolla Pharmaceutical Company
    • InterMune Inc.
    • ProMetic Life-Sciences Inc.
    • Genzyme Corporation
    • BioLine Rx Ltd
    • Certa Therapeutics

第 10 章 調查過程

  • 調查過程
    • 數據挖掘
    • 分析
    • 市場估計
    • 驗證
    • 出版物
  • 調查屬性
  • 調查先決條件

Global Kidney Fibrosis Treatment Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Kidney Fibrosis refers to excessive production and deposition of extracellular matrix (ECM) proteins in the kidney interstitium. This excessive production and deposition of ECM causes structural damage, impairment of renal function, and leads to end-stage renal disease (ESRD). Diabetes and Hypertension are two leading causes of Kidney Fibrosis. Apart from these two as infectious glomerulonephritis, renal vasculitis, ureteral obstruction, genetic alterations, and autoimmune diseases among others also causes Kidney Fibrosis. The increasing incidence of chronic kidney diseases and rowing awareness towards renal fibrosis treatment as well as strategic initiatives from leading market player are key factors accelerating the market growth.

According to the Centers for Disease Control & Prevention - as of 2021, around 37 million US individual are affected by chronic kidney diseases, witnessing for over 15% of all US adults. Moreover, as per National Kidney Foundation estimates- in the United States more than 1 in 7 adults are diagnosed with chronic kidney disease. In addition, around 90% of individuals with kidney disease are not aware about their disease. Also, rising number of favorable initiatives from government authorities and increasing prevalence of lifestyle diseases would create lucrative growth prospectus for the market over the forecast period. However, complex process associated with regulatory approvals stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Kidney Fibrosis Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America the leading region in terms of market share owing to increasing prevalence of chronic kidney diseases as well as favorable initiatives from government authorities in the region. Whereas Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising healthcare spending as well as growing prevalence of lifestyle diseases such as hypertension and diabetes in the region.

Major market players included in this report are:

Merck & Co.

F. Hoffman-La Roche Ltd.

Pfizer Inc.

Galectin Therapeutics

La Jolla Pharmaceutical Company

InterMune Inc.

ProMetic Life-Sciences Inc.

Genzyme Corporation

BioLine Rx Ltd

Certa Therapeutics

Recent Developments in the Market:

  • In March 2022, Zydus Lifesciences received approval for its New Drug Application (NDA) named Oxemia from the Drug Controller General of India (DCGI). The new drug Oxemia, would be a first-of-its-kind oral treatment in India for anaemia associated with chronic kidney disease (CKD)
  • In August 2022, Bayer launched a new drug named finerenone for treatment of chronic kidney disease associated with type-2 diabetes in India. This new drug would be sold in India under brand name Kerendia.
  • In August 2022, USA based Children's Hospital of Philadelphia (CHOP) and Penn Medicine jointly announced the launch of Penn-CHOP Kidney Innovation Center. This new center would be first-of-its-kind and would work towards advance research for the early detection, prevention, and treatment of kidney disease and its associated complications.

Global Kidney Fibrosis Treatment Market Report Scope:

Historical Data: 2019-2020-2021

Base Year for Estimation: 2021

Forecast period: 2022-2029

Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

Segments Covered Therapeutics, End User, Region

Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

Customization Scope Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Therapeutics

Angiotensin II receptor blockers (ARBs)

Angiotensin Converting Enzyme (ACE) inhibitors

Pirfenidone

Renin Inhibitors

Vasopeptidase Inhibitors

By End User

Hospital

Clinics

Home Treatment

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Kidney Fibrosis Treatment Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Kidney Fibrosis Treatment Market, by Therapeutics, 2019-2029 (USD Billion)
    • 1.2.3. Kidney Fibrosis Treatment Market, by End User, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Kidney Fibrosis Treatment Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Kidney Fibrosis Treatment Market Dynamics

  • 3.1. Kidney Fibrosis Treatment Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing incidence of chronic kidney diseases.
      • 3.1.1.2. Growing awareness towards renal fibrosis treatment.
      • 3.1.1.3. Strategic initiatives from leading market players.
    • 3.1.2. Market Challenges
      • 3.1.2.1. Complex regulatory approval procedures.
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Increasing number of favourable initiatives from government authorities.
      • 3.1.3.2. Rising prevalence of lifestyle diseases.

Chapter 4. Global Kidney Fibrosis Treatment Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Investment Adoption Model
  • 4.5. Analyst Recommendation & Conclusion
  • 4.6. Top investment opportunity
  • 4.7. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Kidney Fibrosis Treatment Market, by Therapeutics

  • 6.1. Market Snapshot
  • 6.2. Global Kidney Fibrosis Treatment Market by Therapeutics, Performance - Potential Analysis
  • 6.3. Global Kidney Fibrosis Treatment Market Estimates & Forecasts by Therapeutics 2019-2029 (USD Billion)
  • 6.4. Kidney Fibrosis Treatment Market, Sub Segment Analysis
    • 6.4.1. Angiotensin II receptor blockers (ARBs)
    • 6.4.2. Angiotensin Converting Enzyme (ACE) inhibitors
    • 6.4.3. Pirfenidone
    • 6.4.4. Renin Inhibitors
    • 6.4.5. Vasopeptidase Inhibitors

Chapter 7. Global Kidney Fibrosis Treatment Market, by End User

  • 7.1. Market Snapshot
  • 7.2. Global Kidney Fibrosis Treatment Market by End User, Performance - Potential Analysis
  • 7.3. Global Kidney Fibrosis Treatment Market Estimates & Forecasts by End User 2019-2029 (USD Billion)
  • 7.4. Kidney Fibrosis Treatment Market, Sub Segment Analysis
    • 7.4.1. Hospital
    • 7.4.2. Clinics
    • 7.4.3. Home Treatment

Chapter 8. Global Kidney Fibrosis Treatment Market, Regional Analysis

  • 8.1. Kidney Fibrosis Treatment Market, Regional Market Snapshot
  • 8.2. North America Kidney Fibrosis Treatment Market
    • 8.2.1. U.S. Kidney Fibrosis Treatment Market
      • 8.2.1.1. Therapeutics breakdown estimates & forecasts, 2019-2029
      • 8.2.1.2. End User breakdown estimates & forecasts, 2019-2029
    • 8.2.2. Canada Kidney Fibrosis Treatment Market
  • 8.3. Europe Kidney Fibrosis Treatment Market Snapshot
    • 8.3.1. U.K. Kidney Fibrosis Treatment Market
    • 8.3.2. Germany Kidney Fibrosis Treatment Market
    • 8.3.3. France Kidney Fibrosis Treatment Market
    • 8.3.4. Spain Kidney Fibrosis Treatment Market
    • 8.3.5. Italy Kidney Fibrosis Treatment Market
    • 8.3.6. Rest of Europe Kidney Fibrosis Treatment Market
  • 8.4. Asia-Pacific Kidney Fibrosis Treatment Market Snapshot
    • 8.4.1. China Kidney Fibrosis Treatment Market
    • 8.4.2. India Kidney Fibrosis Treatment Market
    • 8.4.3. Japan Kidney Fibrosis Treatment Market
    • 8.4.4. Australia Kidney Fibrosis Treatment Market
    • 8.4.5. South Korea Kidney Fibrosis Treatment Market
    • 8.4.6. Rest of Asia Pacific Kidney Fibrosis Treatment Market
  • 8.5. Latin America Kidney Fibrosis Treatment Market Snapshot
    • 8.5.1. Brazil Kidney Fibrosis Treatment Market
    • 8.5.2. Mexico Kidney Fibrosis Treatment Market
  • 8.6. Rest of The World Kidney Fibrosis Treatment Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. Merck & Co.
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. F. Hoffman-La Roche Ltd.
    • 9.2.3. Pfizer Inc
    • 9.2.4. Galectin Therapeutics
    • 9.2.5. La Jolla Pharmaceutical Company
    • 9.2.6. InterMune Inc.
    • 9.2.7. ProMetic Life-Sciences Inc.
    • 9.2.8. Genzyme Corporation
    • 9.2.9. BioLine Rx Ltd
    • 9.2.10. Certa Therapeutics

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Kidney Fibrosis Treatment Market, report scope
  • TABLE 2. Global Kidney Fibrosis Treatment Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Kidney Fibrosis Treatment Market estimates & forecasts by Therapeutics 2019-2029 (USD Billion)
  • TABLE 4. Global Kidney Fibrosis Treatment Market estimates & forecasts by End User 2019-2029 (USD Billion)
  • TABLE 5. Global Kidney Fibrosis Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 6. Global Kidney Fibrosis Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Kidney Fibrosis Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Kidney Fibrosis Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Kidney Fibrosis Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Kidney Fibrosis Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Kidney Fibrosis Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Kidney Fibrosis Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Kidney Fibrosis Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. Global Kidney Fibrosis Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. U.S. Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 16. U.S. Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 17. U.S. Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 18. Canada Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 19. Canada Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 20. Canada Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 21. UK Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 22. UK Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 23. UK Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 24. Germany Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 25. Germany Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 26. Germany Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 27. France Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 28. France Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 29. France Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 30. Italy Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 31. Italy Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 32. Italy Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 33. Spain Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 34. Spain Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 35. Spain Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 36. RoE Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 37. RoE Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 38. RoE Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 39. China Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 40. China Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 41. China Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 42. India Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 43. India Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 44. India Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 45. Japan Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 46. Japan Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 47. Japan Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 48. South Korea Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 49. South Korea Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 50. South Korea Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 51. Australia Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 52. Australia Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 53. Australia Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 54. RoAPAC Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 56. RoAPAC Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 57. Brazil Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 58. Brazil Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 59. Brazil Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 60. Mexico Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 61. Mexico Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 62. Mexico Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 63. RoLA Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 64. RoLA Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 65. RoLA Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 66. Row Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 67. Row Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 68. Row Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 69. List of secondary sources, used in the study of global Kidney Fibrosis Treatment Market
  • TABLE 70. List of primary sources, used in the study of global Kidney Fibrosis Treatment Market
  • TABLE 71. Years considered for the study
  • TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Kidney Fibrosis Treatment Market, research methodology
  • FIG 2. Global Kidney Fibrosis Treatment Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Kidney Fibrosis Treatment Market, key trends 2021
  • FIG 5. Global Kidney Fibrosis Treatment Market, growth prospects 2022-2029
  • FIG 6. Global Kidney Fibrosis Treatment Market, porters 5 force model
  • FIG 7. Global Kidney Fibrosis Treatment Market, pest analysis
  • FIG 8. Global Kidney Fibrosis Treatment Market, value chain analysis
  • FIG 9. Global Kidney Fibrosis Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Kidney Fibrosis Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Kidney Fibrosis Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Kidney Fibrosis Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Kidney Fibrosis Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Kidney Fibrosis Treatment Market, regional snapshot 2019 & 2029
  • FIG 15. North America Kidney Fibrosis Treatment Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Kidney Fibrosis Treatment Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Kidney Fibrosis Treatment Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Kidney Fibrosis Treatment Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Kidney Fibrosis Treatment Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable